Phase i clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

British Journal of Cancer

Volumn 106, Issue 1, 2012, Pages 85-91

  Algazi, A P ^a   Weber, J S ^b   Andrews, S C ^b   Urbas, P ^b   Munster, P N ^a   Deconti, R C ^b   Hwang, J ^a   Sondak, V K ^b   Messina, J L ^b   McCalmont, T ^a   Daud, A I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

biomarkers; dacarbazine; dasatinib; melanoma; Src

Indexed keywords

B RAF KINASE; DACARBAZINE; DASATINIB;

ADULT; AGED; ANEMIA; ARTICLE; ATELECTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSAESTHESIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOOT PAIN; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEART INFARCTION; HICCUP; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE C KIT; ONCOGENE N RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; SATIETY; SIDE EFFECT; STANDING; SURVIVAL RATE; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; TONGUE SWELLING; TREATMENT RESPONSE; TUMOR BIOPSY; WEAKNESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PYRIMIDINES; SRC-FAMILY KINASES; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT OUTCOME;

EID: 84855345509     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.514     Document Type: Article

References (53)

1. Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1): S11-S14
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116 (Pubitemid 29318842)
3. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201
4. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz III F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Can Res 14: 6821-6828
5. Boukerche H, Aissaoui H, Prévost C, Hirbec H, Das SK, Su Z, Sarkar D, Fisher PB (2010) Src kinase activation is mandatory for MDA-9/syntenin- mediated activation of nuclear factor-kappaB. Oncogene 29: 3054-3066
6. Buettner R, Mesa T, Vultur A, Lee F, Jove R (2008) Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 6: 1766-1774
7. Carvajal R, Chapman P, Wolchok J, Cane L, Teitcher J, Lutzky J, Pavlick A, Bastian BC, Antonescu CR, Schwartz GK (2009) A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 27(Suppl 15s): abstr 9001
8. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305: 2327-2334
9. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen vs dacarbazine in patients with metastatic melanoma. J Clin Oncol 17: 2745-2751 (Pubitemid 29415231)
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516
11. ClinicalTrials.gov (no date) Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma That Cannot Be Removed By Surgery-Full Text View. Retrieved 27 October 2010, from http://www.clinicaltrials.gov/ct2/show/NCT00700882?termdasatinib+melanoma& rank3
12. Eustace A, Mahgoub T, Kennedy S, Crown J, Larkin A, Tryfonopoulos D, O'Driscoll L, Clynes M, O'Donovan N (2010) Targeting SRC kinase (SRC) in melanoma cells. J Clin Oncol 28(Suppl 15s): abstr 8584
13. Eustace AJ, Crown J, Clynes M, O'Donovan N (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 6: 53
14. Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, Biffoni M, Spadaro F, Lisanti MP, Sargiacomo M, Carè A (2009) Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer 125: 1514-1522
15. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319-326 (Pubitemid 47596452)
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819
17. Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, Diener KR, Hayball JD (2010) Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biol Ther 10: 715-727. Retrieved from http://www.ncbi.nlm.nih. gov/pubmed/20676039
18. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29: 2904-2909
19. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L, Dobrovic A, McArthur GA (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102: 1219-1223
20. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97: 263-274 (Pubitemid 43945756)
21. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
22. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI (2009) Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 19: 167-175
23. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238 (Pubitemid 46424242)
24. Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH (2005) Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Res 65: 1814-1821 (Pubitemid 40478609)
25. Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21: 187-190 (Pubitemid 29070364)
26. Jallal H, Valentino M, Chen G, Boschelli F, Ali S, Rabbani SA (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67: 1580-1588 (Pubitemid 46383382)
27. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300
28. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM (2011) In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res 24: 386-389
29. Journe F, Wiedig M, Morandini R, Sales F, Ghanem G, Awada A (2010) cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines. Eur J Cancer 8: 83-84, abstract 254
30. Kefford R, Arkenau H, Brown M, Millward M, Infante J, Long G, Ouellet D, Curtis M, Lebowitz PF, Falchook GS (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J ClinOncol 28(Suppl 15s): abstr 8503
31. Kim LC, Song L, Haura EB (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595
32. Kline CLB, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB (2008) Src kinase induces tumor formation in the c-SRC C57BL/6 mouse. Int J Cancer 122: 2665-2673 (Pubitemid 351631367)
33. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M (2011) A phase 2 trial of dasatinib in advanced melanoma. Cancer 117: 2202-2208
34. Korn EL, Liu P, Lee SJ, Chapman JW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J Clin Oncol 26: 527-534 (Pubitemid 351264344)
35. Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos AS, Carter B, Turkson J, Jove R (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629
36. Luikart SD, Kennealey GT, Kirkwood JM (1984) Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum vs dacarbazine in malignant melanoma. J Clin Oncol 2: 164-168 (Pubitemid 14138403)
37. Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21: 492-493 (Pubitemid 351990966)
38. Maat W, El Filali M, Dirks-Mulder A, Luyten GPM, Gruis NA, Desjardins L, Boender P, Jager MJ, van der Velden PA (2009) Episodic Src activation in uveal melanoma revealed by kinase activity profiling. Br J Cancer 101: 312-319
39. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide vs dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166 (Pubitemid 30036349)
40. Morgan L, Gee J, Pumford S, Farrow L, Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R, Hiscox S (2009) Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8: 1550-1558
41. Nam S, Kim D, Cheng JQ, Zhang S, Lee J, Buettner R, Mirosevich J, Lee FY, Jove R (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189 (Pubitemid 41507982)
42. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010 (Pubitemid 35252974)
43. Ratain MJ, Mick R, Schilsky RL, Siegler M (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85: 1637-1643 (Pubitemid 23315422)
44. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller Jr WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526
45. Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H, Kapp A, Gutzmer R (2008) Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 99: 2065-2069
46. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker E, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G (2006) Dacarbazine (DTIC) vs vaccination with autologous peptide-pulsed den dritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17: 563-570
47. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66: 5542-5548 (Pubitemid 43927102)
48. Torres-Cabala CA, Wang W, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D (2009) Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22: 1446-1456
49. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168: 962-972 (Pubitemid 43327748)
50. Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F (2010) CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway. Cancer Res 70: 7489-7499
51. Wang X, Reeves K, Luo FR, Xu L, Lee F, Clark E, Huang F (2007) Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 8: R255
52. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA (2009) Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8: 2079-2085
53. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83